– USA, CA – Endeavor BioMedicines, a clinical-stage company developing therapies for fibrotic disease and oncology, today announced the appointment of Dr. Enoch Kariuki (Pharm.D.) to its Board of Directors.
“Dr. Kariuki is an excellent addition to our esteemed board of directors, who are helping us advance our pipeline of therapies for patients with fibrosis and cancer,” said co-founder, CEO and chairman, Dr- John Hood.
Dr. Enoch Kariuki is an established life sciences executive with extensive strategic, operational, and financial experience.
Dr. Kariuki has more than fifteen years of experience in healthcare strategy, life sciences investment banking, venture capital, and business development. Most recently, he served as CEO of Lengo Therapeutics (acquired by Blueprint Medicines). Previously, Dr. Kariuki served as CFO of VelosBio (acquired by Merck), where he led all finance-related and investor relations functions. Before VelosBio, he served as SVP of Corporate Development, at Synthorx, where he led the company’s IPO, managed relationships with bankers, sell-side equity analysts, and investors, and headed the business development process that concluded with the sale of Synthorx to Sanofi. Before Synthorx, Dr. Kariuki was VP at H.I.G. Capital, a $50 billion+ private equity firm, where he invested in and served on the boards of multiple life sciences companies.
“Endeavor BioMedicines’ pipeline of differentiated therapeutic options has the potential to make a significant difference in the treatment of fibrotic lung diseases as well as cancer,” said Dr. Kariuki. “This, coupled with a talented and focused management team equipped to execute on its development strategy, makes this an incredibly promising and compelling company. I look forward to working closely with the other members of the Board and management team to bring important new treatment options to patients in need.”
About Endeavor BioMedicines
Endeavor BioMedicines, Inc., is a clinical-stage company developing novel therapies for fibrosis and oncology. The Company combines best-in-class therapeutics with an evolved understanding of terminal diseases to develop medicines with the potential to reverse severe health conditions. Endeavor BioMedicines’ lead program, ENV-101, is a Hedgehog signaling inhibitor currently in Phase 2 studies treating idiopathic pulmonary fibrosis. The second program is a HER3-targeted antibody-drug conjugate that will begin clinical development in 2024 for the treatment of multiple solid tumors. Endeavor BioMedicines has an innovative and focused team that works to develop therapeutics that help patients feel better and live longer.
SOURCE: https://endeavorbiomedicines.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
